Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10966
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGan, Hui Ken
dc.contributor.authorAzad, Arun Aen
dc.contributor.authorCher, Lawrence Men
dc.contributor.authorMitchell, Paul L Ren
dc.date.accessioned2015-05-16T00:32:39Z
dc.date.available2015-05-16T00:32:39Z
dc.date.issued2009-12-24en
dc.identifier.citationNeuro-oncology 2009; 12(2): 212-5en
dc.identifier.govdoc20150388en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10966en
dc.description.abstractNeurolymphomatosis (NL) is an uncommon syndrome of peripheral or cranial nerve root dysfunction secondary to infiltration by B-cell non-Hodgkin's lymphoma (NHL). A high index of suspicion is required as presenting symptoms are varied, conventional radiology has only modest sensitivity, and pathological diagnosis is often difficult. Treatment with chemotherapy alone has an objective response rate of 82%, although long-term outcomes are highly variable. This case series describes outcomes in four patients whose management incorporated PET scanning and the use of rituximab in combination with chemotherapy. PET scanning could often diagnose NL where other diagnostic modalities were non-diagnostic. Although combination therapy with rituximab and chemotherapy has been shown to be superior to chemotherapy alone in other forms of NHL, this does not appear to be the case in patients with NL. This may reflect the inability of rituximab to adequately penetrate into the central and peripheral nervous system. This is supported by the common finding that patients will relapse solely with NL despite on-going complete remission at sites outside the nervous system. The prognosis of these patients is poor, with the disease often following a progressive course despite treatment.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAntibodies, Monoclonal.administration & dosageen
dc.subject.otherAntibodies, Monoclonal, Murine-Deriveden
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherLymphoma, Large B-Cell, Diffuse.diagnosis.drug therapyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPeripheral Nervous System Neoplasms.diagnosis.drug therapyen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherTreatment Outcomeen
dc.titleNeurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeuro-oncologyen
dc.identifier.affiliationAustin-Ludwig Medical Oncology Department, 145 Stucttey Road, Heidelberg 3084, Melbourne, Australiaen
dc.identifier.affiliationhui.gan@ludwig.edu.auen
dc.identifier.doi10.1093/neuonc/nop021en
dc.description.pages212-5en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20150388en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.